Resumen de acción J7Z Jazz Pharmaceuticals plc identifica, desarrolla y comercializa productos farmacéuticos para necesidades médicas no cubiertas en Estados Unidos, Europa e internacionalmente. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Jazz Pharmaceuticals plc Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Jazz Pharmaceuticals Precios históricos de las acciones Precio actual de la acción US$119.90 Máximo en las últimas 52 semanas US$122.90 Mínimo de 52 semanas US$92.40 Beta 0.57 Cambio en 1 mes 3.85% Variación en 3 meses 20.77% Cambio de 1 año 5.31% Variación en 3 años 3.32% Variación en 5 años -7.77% Variación desde la OPV 830.90%
Noticias y actualizaciones recientes Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 Dec 17
Jazz Pharmaceuticals plc to Showcase New Real-World Evidence Reinforcing Epidiolex (Cannabidiol) Benefits Dec 07
Jazz Pharmaceuticals plc Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include Zanidatamab-Hrii (Ziihera®?) Dec 05
Jazz Pharmaceuticals plc to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting Dec 03
Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC) Nov 21
New minor risk - Insider selling Nov 15 Ver más actualizaciones Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 Dec 17
Jazz Pharmaceuticals plc to Showcase New Real-World Evidence Reinforcing Epidiolex (Cannabidiol) Benefits Dec 07
Jazz Pharmaceuticals plc Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include Zanidatamab-Hrii (Ziihera®?) Dec 05
Jazz Pharmaceuticals plc to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting Dec 03
Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC) Nov 21
New minor risk - Insider selling Nov 15
Executive VP & Chief Legal Officer recently sold €426k worth of stock Nov 15
Third quarter 2024 earnings released: EPS: US$3.50 (vs US$2.33 in 3Q 2023) Nov 07
Jazz Pharmaceuticals plc Presents New Data at Psych Congress 2024 Confirming Xywav®? (Calcium, Potent, and Sodium Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia Nov 01
Jazz Pharmaceuticals plc to Report Q3, 2024 Results on Nov 06, 2024 Oct 24
Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (Lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Oct 15
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from FTSE All-World Index (USD) Sep 23
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024 Sep 16
gJazz Pharmaceuticals plc to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex/Epidyolex®? (Cannabidiol) At the European Epilepsy Congress 2024 Sep 05
Jazz Pharmaceuticals plc Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies Aug 23
Second quarter 2024 earnings released: EPS: US$2.68 (vs US$1.63 in 2Q 2023) Aug 02
Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares. Aug 02 Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares. Aug 01
Jazz Pharmaceuticals plc Elect Laura Hamill to the Board of Directors Jul 26
Jazz Pharmaceuticals plc to Report Q2, 2024 Results on Jul 25, 2024 Jul 18
Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer Jul 11
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 2500 Growth Index Jul 03
Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor Jun 20
Jazz Pharmaceuticals plc, Annual General Meeting, Jul 25, 2024 Jun 06
New minor risk - Insider selling Jun 02
Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board Jun 02
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 May 31
Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application (BLA) for Zanidatamab May 30
Executive VP & Chief Legal Officer recently sold €509k worth of stock May 09
First quarter 2024 earnings released: US$0.23 loss per share (vs US$1.09 profit in 1Q 2023) May 02
Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024 May 02
Jazz Pharmaceuticals plc to Report Q1, 2024 Results on May 01, 2024 Apr 19
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Apr 02
Senior VP & Chief Accounting Officer recently sold €401k worth of stock Mar 13
Executive VP & CFO recently bought €1.3m worth of stock Mar 10
New minor risk - Earnings quality Mar 03
Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024 Feb 29
Full year 2023 earnings released: EPS: US$6.55 (vs US$3.58 loss in FY 2022) Feb 29
Jazz Pharmaceuticals Announces Board Changes Feb 27 Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024
Jazz Pharmaceuticals plc to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
Insufficient new directors Jan 01
Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023 Dec 16
Jazz Pharmaceuticals plc to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Annual Meeting Dec 02
Third quarter 2023 earnings released: EPS: US$2.33 (vs US$0.31 loss in 3Q 2022) Nov 09
Jazz Pharmaceuticals plc to Report Q3, 2023 Results on Nov 08, 2023 Oct 26
Jazz Pharmaceuticals plc Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xyw Oct 24
Jazz Pharmaceuticals plc to Present Data from Trials of Bispecific Antibody Zanidatamab and Zepzelca Oct 17
Jazz Pharmaceuticals plc Receives European Commission Approval for Enrylaze® for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Sep 22 Jazz Pharmaceuticals plc Announces Chief Financial Officer Changes, October 1, 2023
Jazz Pharmaceuticals plc Revises Earnings Guidance for the Year 2023 Aug 10
Second quarter 2023 earnings released: EPS: US$1.63 (vs US$0.56 in 2Q 2022) Aug 10
Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation Jul 30
Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation Jul 29
Jazz Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023 Jul 28
Jazz Pharmaceuticals plc, Annual General Meeting, Aug 03, 2023 Jun 17
Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers Jun 03
Jazz Pharmaceuticals plc Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023 Jun 01
Insider recently sold €734k worth of stock May 23
First quarter 2023 earnings released: EPS: US$1.09 (vs US$0.027 in 1Q 2022) May 11
Jazz Pharmaceuticals plc Affirms Revenue Guidance for the Year 2023 May 11
Insider recently sold €276k worth of stock Mar 15
Full year 2022 earnings released: US$3.58 loss per share (vs US$5.52 loss in FY 2021) Mar 03
Jazz Pharmaceuticals plc to Report Q4, 2022 Results on Mar 01, 2023 Feb 16
Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma Jan 20
Insider recently sold €265k worth of stock Dec 16
Independent Non-Executive Director recently sold €62k worth of stock Dec 09
Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies Dec 06
Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes At the 2022 American Epilepsy Society Annual Meeting Nov 29
Independent Director recently sold €1.0m worth of stock Nov 27
Executive VP & Chief Legal Officer recently sold €480k worth of stock Nov 20
Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) Nov 19
Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.86 loss in 3Q 2021) Nov 11
Jazz Pharmaceuticals plc Raises Earnings Guidance for the Full Year 2022 Nov 10
Jazz Pharmaceuticals plc to Report Q3, 2022 Results on Nov 09, 2022 Oct 27
Jazz Pharmaceuticals plc Reiterates Revenue Guidance for the Full Year 2022 Sep 08
Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex Epidyolex (Cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures Aug 19
Independent Director recently sold €176k worth of stock Aug 11
Second quarter 2022 earnings released: EPS: US$0.56 (vs US$6.11 loss in 2Q 2021) Aug 04
Jazz Pharmaceuticals plc Updates Earnings Guidance for the Year 2022 Aug 04
Jazz Pharmaceuticals plc to Report Q2, 2022 Results on Aug 03, 2022 Jul 21
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity Jun 29
Jazz Pharmaceuticals plc, Annual General Meeting, Jul 28, 2022 Jun 14
Jazz Pharmaceuticals plc Presents Positive Data from Phase 2/3 Trial of Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma At the ASCO 2022 Annual Meeting Jun 08
Senior VP & Chief Accounting Officer recently sold €288k worth of stock May 13
First quarter 2022 earnings released: EPS: US$0.027 (vs US$2.16 in 1Q 2021) May 06
Jazz Pharmaceuticals plc Raises Financial Guidance for the Full Year 2022 May 05
Jazz Pharmaceuticals plc to Report Q1, 2022 Results on May 04, 2022 Apr 21
Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, Including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types Apr 09
Axsome Therapeutics, Inc. (NasdaqGM:AXSM) agreed to acquire Sunosi® from Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) for $53 million. Mar 29
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 03
Jazz Pharmaceuticals plc Provides Revenue Guidance for the Full Year 2022 Mar 03
Jazz Pharmaceuticals plc to Report Fiscal Year 2021 Results on Mar 01, 2022 Feb 16
Jazz Pharmaceuticals plc Completes U.S. FDA Supplemental Biologics License Application for Rylaze Feb 03 Rentabilidad de los accionistas J7Z DE Pharmaceuticals Mercado DE 7D 0.9% 2.2% 0.7% 1Y 5.3% -16.8% 8.4%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: J7Z superó a la industria German Pharmaceuticals, que obtuvo un rendimiento del -16.8% el año pasado.
Rentabilidad vs. Mercado: J7Z obtuvo unos resultados inferiores a los del mercado German, que fueron del 8.4% el año pasado.
Volatilidad de los precios Is J7Z's price volatile compared to industry and market? J7Z volatility J7Z Average Weekly Movement 4.7% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: J7Z no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de J7Z (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Jazz Pharmaceuticals plc identifica, desarrolla y comercializa productos farmacéuticos para necesidades médicas no cubiertas en Estados Unidos, Europa e internacionalmente. La empresa ofrece Xywav para la cataplejía o la somnolencia diurna excesiva (EDS) con narcolepsia e hipersomnia idiopática; Xyrem para tratar la cataplejía o la EDS con narcolepsia; Epidiolex para las convulsiones asociadas a los síndromes de Lennox-Gastaut y Dravet, o al complejo de esclerosis tuberosa; Zepzelca para tratar el cáncer de pulmón metastásico de células pequeñas, o con progresión de la enfermedad en o después de la quimioterapia basada en platino; Rylaze para la leucemia linfoblástica aguda o el linfoma linfoblástico; Enrylaze para tratar la leucemia linfoblástica aguda y el linfoma linfoblástico; Defitelio para tratar la enfermedad veno-oclusiva hepática grave; y Vyxeos para la leucemia mieloide aguda de reciente diagnóstico relacionada con la terapia. También desarrolla Zanidatamab para tratar el adenocarcinoma gastroesofágico (GEA) que expresa HER2, y pacientes con GEA metastásico que expresa HER2; Zepzelca para el tratamiento de pacientes con tumores sólidos selectos en recaída/refractarios basado en la respuesta limitada en tres cohortes de tumores sólidos; JZP815, un inhibidor pan-RAF de la cinasa que se dirige a componentes de la proteína cinasa activada por mitógenos; JZP898, una molécula de interferón alfa activada condicionalmente; Epidiolex para tratar LGS, DS y TSC; Suvecaltamide para tratar el temblor de la enfermedad de Parkinson; JZP150, un programa inhibidor de la amida hidrolasa de ácidos grasos para tratar el trastorno de estrés postraumático; y JZP441 para tratar la narcolepsia, IH y otros trastornos del sueño.
Mostrar más Resumen de fundamentos de Jazz Pharmaceuticals plc ¿Cómo se comparan los beneficios e ingresos de Jazz Pharmaceuticals con su capitalización de mercado? Estadísticas fundamentales de J7Z Capitalización bursátil €7.25b Beneficios(TTM ) €451.30m Ingresos (TTM ) €3.89b
16.2x Ratio precio-beneficio (PE)
1.9x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de J7Z Ingresos US$3.99b Coste de los ingresos US$294.67m Beneficio bruto US$3.70b Otros gastos US$3.23b Beneficios US$463.16m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) 7.66 Margen bruto 92.62% Margen de beneficio neto 11.60% Ratio deuda/patrimonio 146.6%
¿Cómo se ha desempeñado J7Z a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/02 06:08 Precio de las acciones al final del día 2025/01/02 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Jazz Pharmaceuticals plc está cubierta por 51 analistas. 19 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Joel Beatty Baird Ishan Majumdar Baptista Research Richard Silver Barclays
Mostrar 48 más analistas 
